BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry 2013;52:8246-60. [PMID: 24144388 DOI: 10.1021/bi401119m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
3 Tautermann CS, Seeliger D, Kriegl JM. What can we learn from molecular dynamics simulations for GPCR drug design? Comput Struct Biotechnol J 2015;13:111-21. [PMID: 25709761 DOI: 10.1016/j.csbj.2014.12.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
4 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
5 Cavasotto CN, Palomba D. Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. Chem Commun 2015;51:13576-94. [DOI: 10.1039/c5cc05050b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 5.1] [Reference Citation Analysis]
6 Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Di Pizio A, Kruetzfeldt LM, Cheled-Shoval S, Meyerhof W, Behrens M, Niv MY. Ligand binding modes from low resolution GPCR models and mutagenesis: chicken bitter taste receptor as a test-case. Sci Rep 2017;7:8223. [PMID: 28811548 DOI: 10.1038/s41598-017-08344-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
8 Heifetz A, Storer RI, McMurray G, James T, Morao I, Aldeghi M, Bodkin MJ, Biggin PC. Application of an Integrated GPCR SAR-Modeling Platform To Explain the Activation Selectivity of Human 5-HT2C over 5-HT2B. ACS Chem Biol 2016;11:1372-82. [PMID: 26900768 DOI: 10.1021/acschembio.5b01045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
9 Mignot EJ. History of narcolepsy at Stanford University. Immunol Res 2014;58:315-39. [PMID: 24825774 DOI: 10.1007/s12026-014-8513-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
10 Biggin PC, Aldeghi M, Bodkin MJ, Heifetz A. Beyond Membrane Protein Structure: Drug Discovery, Dynamics and Difficulties. Adv Exp Med Biol 2016;922:161-81. [PMID: 27553242 DOI: 10.1007/978-3-319-35072-1_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Heifetz A, Aldeghi M, Chudyk EI, Fedorov DG, Bodkin MJ, Biggin PC. Using the fragment molecular orbital method to investigate agonist-orexin-2 receptor interactions. Biochem Soc Trans 2016;44:574-81. [PMID: 27068972 DOI: 10.1042/BST20150250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
12 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bai Q, Pérez-Sánchez H, Shi Z, Li L, Shi D, Liu H, Yao X. Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations. Chem Biol Drug Des 2018;92:1221-31. [PMID: 29450984 DOI: 10.1111/cbdd.13181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Perkins A, Phillips JL, Kerkvliet NI, Tanguay RL, Perdew GH, Kolluri SK, Bisson WH. A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain. Biology (Basel) 2014;3:645-69. [PMID: 25329374 DOI: 10.3390/biology3040645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
15 Heifetz A, Schertler GF, Seifert R, Tate CG, Sexton PM, Gurevich VV, Fourmy D, Cherezov V, Marshall FH, Storer RI, Moraes I, Tikhonova IG, Tautermann CS, Hunt P, Ceska T, Hodgson S, Bodkin MJ, Singh S, Law RJ, Biggin PC. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. Naunyn Schmiedebergs Arch Pharmacol 2015;388:883-903. [PMID: 25772061 DOI: 10.1007/s00210-015-1111-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
16 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep 2015;7:51-61. [PMID: 26045680 DOI: 10.2147/NSS.S56077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
17 Yokoi S, Mitsutake A. Characteristic structural difference between inactive and active states of orexin 2 receptor determined using molecular dynamics simulations. Biophys Rev. [DOI: 10.1007/s12551-021-00862-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
19 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zhang X, Cross JB, Romero J, Heifetz A, Humphries E, Hall K, Wu Y, Stucka S, Zhang J, Chandonnet H, Lippa B, Ryan MD, Baber JC. In-silico guided discovery of novel CCR9 antagonists. J Comput Aided Mol Des 2018;32:573-82. [DOI: 10.1007/s10822-018-0113-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Heifetz A, James T, Morao I, Bodkin MJ, Biggin PC. Guiding lead optimization with GPCR structure modeling and molecular dynamics. Current Opinion in Pharmacology 2016;30:14-21. [DOI: 10.1016/j.coph.2016.06.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
22 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tautermann CS. GPCR Homology Model Generation for Lead Optimization. Methods Mol Biol 2018;1705:115-31. [PMID: 29188560 DOI: 10.1007/978-1-4939-7465-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Tikhonova IG, Gigoux V, Fourmy D. Understanding Peptide Binding in Class A G Protein-Coupled Receptors. Mol Pharmacol 2019;96:550-61. [PMID: 31436539 DOI: 10.1124/mol.119.115915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
25 Heifetz A, Bodkin MJ, Biggin PC. Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists. J Med Chem 2015;58:7928-30. [PMID: 26375584 DOI: 10.1021/acs.jmedchem.5b01394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
26 Karhu L, Turku A, Xhaard H. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. BMC Struct Biol 2015;15:9. [PMID: 25957175 DOI: 10.1186/s12900-015-0036-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]